Desmopressin as a Treatment for Enuresis

Dimson, S. B.

doi:10.1016/s0140-6736(77)92467-9

Cited by 69 publications

(18 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Plasma vasopressin is at undetectable levels in many such patients [10], therefore desmopressin [a synthetic analogue of arginine vasopressin) seems to be a suitable therapeutic choice for patients with nocturia. As found in previous studies, [13,15,17] desmopressin treatment is associated with a decrease in nocturnal urine output.The main aim of the present study was to investigate the efficacy of oral desmopressin in reduction in episodes of nocturnal voids, which is the main complaint of subjects with nocturia. The threshold chosen for clinical response was a ≥ 50% reduction in nocturnal void based on previous studies [11,18].…”

Section: Discussionsupporting

confidence: 84%

Oral Desmopressin in the Management of Adults with Nocturia

Gooran¹,

Nasirmohtaram²,

Mohseni³

et al. 2011

OJU

View full text Add to dashboard Cite

We investigated the efficacy of oral desmopressin in the treatment of adult nocturia. In an analytical study between 2007-2009 in Zahedan-Iran, Thirty patients ≥55 years with verified nocturia (≥two voids/night) were enrolled. Patients with a history of an obstructive cause of nocturia, those with diseases getting worse by the anti-diuretic affect of desmopressin and those with well-defined curable causes (e.g. cystitis) were excluded. Patients received 0.2 mg of oral desmopressin at bed time for a period of 3 weeks. p < 0.05 was taken as the significant level. All 30 patients enrolled completed the trial. Fourteen (47 %) patients receiving desmopressin had fewer than half the number of nocturnal voids relative to base line (p < 0.001). The mean number of nocturnal voids decreased from 4.6 to 2.4 (p < 0.001). Fatigue (10%), headache (3%) and dizziness (3%) were reported. All adverse events were of mild intensity and there were no instances of hyponatremia. Oral desmopressin is an effective treatment in patients with nocturia and is well-tolerated.

show abstract

Section: Discussionsupporting

confidence: 84%

Oral Desmopressin in the Management of Adults with Nocturia

Gooran¹,

Nasirmohtaram²,

Mohseni³

et al. 2011

OJU

View full text Add to dashboard Cite

show abstract

“…As a result of its greater anti-diuretic activity, this synthetic analog was used for many years in patients with insipid diabetes. Dimson [32] in 1977 and Tuvemo [33] in 1978 were the first to test DDAVP in subjects with enuresis. Norgaard, Ritting and coworkers [34 Á/37] determined that nocturnal polyuria was an etiopathogenetic and important factor for enuresis in cases in whom there was no increase in plasmatic AVP.…”

Section: Discussionmentioning

confidence: 99%

Desmopressin is a safe drug for the treatment of enuresis

Gado

Gaizo

Cennamo

et al. 2005

Scandinavian Journal of Urology and Nephrology

View full text Add to dashboard Cite

show abstract

“…Research has shown that a subset of enuretic children do not exhibit the normal diurnal rhythm of ADH secretion and perhaps, wet their beds as a result of increased urine production while sleeping (e.g., Norgaard, Pedersen, & Djurhuss, 1985). Earlier (and subsequent) related research showed desmopressin (DDAVP), an intranasally administered vasopressin analogue, reduced nocturnal enuretic episodes in children (e.g., Dimson, 1977; and see Antidiuretics under Treatment below). However, whether the effectiveness of DDAVP is due to the restoration of insufficient nocturnal ADH or is merely the result of decreased urine volume (due to increased concentration) and thus, not a primary causal variable, is still unknown (Houts, 1991).…”

Section: Nocturnal Polyuriamentioning

confidence: 99%

Enuresis and Encopresis

Friman

Freeman

2010

Handbook of Clinical Psychology Competencies

View full text Add to dashboard Cite

Abstract:In this chapter, we describe the assessment and treatment of enuresis and encopresis. We first review literature on the symptoms, causes, and evidence-based treatments of each condition separately. We also incorporate a discussion of the mechanisms of change underlying effective intervention. Then, using Ryle's (1949) distinction between "knowing how" and "knowing that" as a framework, we discuss the basic competencies one should possess to address these clinical issues. A major reason for distinguishing between the "knowing how" and "knowing that" skill sets is that some clinicians teach and others practice. Based on this framework, we argue that demonstration of basic competency entails the clinician having the skills to conduct effective assessment and treatment of enuresis and/or encopresis, or the skills necessary to tell others (e.g., supervisees) how to do so. These skills include a thorough knowledge of the physiology of urination and defecation, potential pathophysiology of elimination disorders, the ability to effectively interface with medical providers regarding their treatment, and a strong working knowledge of evidence based treatments and their mechanisms of change. In our discussion of expert competency, we use no such distinction between "knowing how" and "knowing that", as an expert should be skilled in both. Further, expert competency in enuresis and encopresis entails the verbal and performance knowledge base to make scholarly contributions to the field, either by conducting one's own research or serving as a consultant to other research programs. Thus, an expert in this area is well poised to contribute to the field of elimination disorders as a master clinician, a specialty supervisor, and/or as a contributing researcher. OverviewChild clinical and pediatric psychologists confront a diverse set of problems that challenge children and their families. Often overlooked, but critically important, is the ability to successfully evaluate and intervene the challenges that may, at first glance, seem either medically based or within the realm of "typical" child behavioral problems. Among the most common, persistent, and stressful presenting complaints in primary medical care for children are two disorders involving developmentally inappropriate elimination of waste -enuresis (urine) and encopresis (feces). Evidence of their commonality and persistence is found in prevalence and age-range estimates. Prevalence estimates range as high 2% of 5-year-old children for encopresis and 25% of 6-year-old children for enuresis and, although both are much less prevalent by the teenage years, they are not rare. For example, as many as 8% of boys and 4% of girls are still enuretic at the age

show abstract

Desmopressin as a Treatment for Enuresis

Cited by 69 publications

References 6 publications

Oral Desmopressin in the Management of Adults with Nocturia

Oral Desmopressin in the Management of Adults with Nocturia

Desmopressin is a safe drug for the treatment of enuresis

Enuresis and Encopresis

Contact Info

Product

Resources

About